LBPH
Price:
$34.86
Market Cap:
$1.36B
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.[Read more]
Industry
Biotechnology
IPO Date
2021-03-12
Stock Exchange
NASDAQ
Ticker
LBPH
According to Longboard Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -16.14. This represents a change of 107.44% compared to the average of -7.78 of the last 4 quarters.
The mean historical PE Ratio of Longboard Pharmaceuticals, Inc. over the last ten years is -6.81. The current -16.14 PE Ratio has changed 23.59% with respect to the historical average. Over the past ten years (40 quarters), LBPH's PE Ratio was at its highest in in the June 2022 quarter at -1.16. The PE Ratio was at its lowest in in the March 2020 quarter at -404.70.
Average
-6.81
Median
-2.76
Minimum
-20.43
Maximum
-1.30
Discovering the peaks and valleys of Longboard Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 94.07%
Maximum Annual PE Ratio = -1.30
Minimum Annual Increase = -85.30%
Minimum Annual PE Ratio = -20.43
Year | PE Ratio | Change |
---|---|---|
2023 | -2.52 | 94.07% |
2022 | -1.30 | -56.80% |
2021 | -3.00 | -85.30% |
The current PE Ratio of Longboard Pharmaceuticals, Inc. (LBPH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.27
5-year avg
-6.81
10-year avg
-6.81
Longboard Pharmaceuticals, Inc.’s PE Ratio is less than Molecular Partners AG (-2.67), less than MediciNova, Inc. (-12.61), less than Anebulo Pharmaceuticals, Inc. (-4.99), less than Champions Oncology, Inc. (-7.94), less than Cyteir Therapeutics, Inc. (-3.52), less than Werewolf Therapeutics, Inc. (-1.64), less than Edgewise Therapeutics, Inc. (-14.14), less than Decibel Therapeutics, Inc. (-1.94), less than Celcuity Inc. (-7.01), less than C4 Therapeutics, Inc. (-3.44), less than Assembly Biosciences, Inc. (-2.10), less than NextCure, Inc. (-0.65), less than Nuvation Bio Inc. (-1.34), less than Graphite Bio, Inc. (-0.13), less than Instil Bio, Inc. (-0.78), less than Sensei Biotherapeutics, Inc. (-0.52), less than Merrimack Pharmaceuticals, Inc. (-8.92), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Design Therapeutics, Inc. (-5.23), less than Ikena Oncology, Inc. (-1.22), less than Stoke Therapeutics, Inc. (-7.92),
Company | PE Ratio | Market cap |
---|---|---|
-2.67 | $182.90M | |
-12.61 | $103.00M | |
-4.99 | $46.68M | |
-7.94 | $57.77M | |
-3.52 | $108.71M | |
-1.64 | $88.28M | |
-14.14 | $1.64B | |
-1.94 | $123.37M | |
-7.01 | $557.67M | |
-3.44 | $374.42M | |
-2.10 | $107.81M | |
-0.65 | $39.73M | |
-1.34 | $692.60M | |
-0.13 | $185.19M | |
-0.78 | $92.68M | |
-0.52 | $15.32M | |
-8.92 | $223.97M | |
-3.11 | $349.21M | |
-5.23 | $264.42M | |
-1.22 | $81.56M | |
-7.92 | $773.92M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Longboard Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Longboard Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Longboard Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Longboard Pharmaceuticals, Inc. (LBPH)?
What is the highest PE Ratio for Longboard Pharmaceuticals, Inc. (LBPH)?
What is the 3-year average PE Ratio for Longboard Pharmaceuticals, Inc. (LBPH)?
What is the 5-year average PE Ratio for Longboard Pharmaceuticals, Inc. (LBPH)?
How does the current PE Ratio for Longboard Pharmaceuticals, Inc. (LBPH) compare to its historical average?